MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
出版年份 2013 全文链接
标题
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
作者
关键词
-
出版物
BLOOD
Volume 121, Issue 20, Pages 4021-4031
出版商
American Society of Hematology
发表日期
2013-03-01
DOI
10.1182/blood-2012-10-460063
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma
- (2012) A. M. Perry et al. BLOOD
- Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
- (2012) Z. Y. Xu-Monette et al. BLOOD
- Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study
- (2012) C. Visco et al. HAEMATOLOGICA
- Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies
- (2012) Kian-Huat Lim et al. IMMUNOLOGICAL REVIEWS
- Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Tina Marie Green et al. JOURNAL OF CLINICAL ONCOLOGY
- Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Nathalie A. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiparametric Flow Cytometry for Identification and Fluorescence Activated Cell Sorting of Five Distinct B-Cell Subpopulations in Normal Tonsil Tissue
- (2011) Malene Krag Kjeldsen et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
- (2011) G. Gutierrez-Garcia et al. BLOOD
- Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
- (2011) Peter Friedl et al. CELL
- BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab
- (2011) J. Iqbal et al. CLINICAL CANCER RESEARCH
- The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study
- (2011) Catherine Thieblemont et al. JOURNAL OF CLINICAL ONCOLOGY
- The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma
- (2011) P Ruminy et al. LEUKEMIA
- B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome
- (2011) Shaoying Li et al. MODERN PATHOLOGY
- The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
- (2010) Paul N. Meyer et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma
- (2010) Matija Snuderl et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Double-hit B-cell lymphomas
- (2010) S. M. Aukema et al. BLOOD
- Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
- (2010) Paul N. Meyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
- (2009) N. A. Johnson et al. BLOOD
- A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy
- (2009) W. W.L. Choi et al. CLINICAL CANCER RESEARCH
- Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas
- (2009) Heidi Nyman et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations
- (2009) N. Tomita et al. HAEMATOLOGICA
- Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations
- (2009) N Niitsu et al. LEUKEMIA
- Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP
- (2009) Heidi Nyman et al. MODERN PATHOLOGY
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
- (2009) Mara Compagno et al. NATURE
- Stromal Gene Signatures in Large-B-Cell Lymphomas
- (2008) G. Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
- (2008) G. Lenz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab
- (2007) Yasodha Natkunam et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started